Triple Negative Breast Cancer Treatment Market

Triple Negative Breast Cancer Treatment Market Outlook (2023-2033)

Worldwide revenue from the triple-negative breast cancer treatment market stands at US$ 614.8 Mn in 2022, with the global market estimated to expand at a CAGR of 3.7% to reach US$ 922.3 Mn by the end of 2033.

As assessed by Persistence Market Research, hospital pharmacies contributed the largest share of 70.2% among the distribution channel in 2022 globally. The triple-negative breast cancer treatment market holds 2.0% of the global breast cancer treatment market valued at US$ 30.7 Bn in 2022.

Sales Analysis of Triple Negative Breast Cancer Treatment Market from 2013 to 2022 Vs Market Outlook for 2023 to 2033

The global market for triple-negative breast cancer treatment recorded a historic CAGR of 4.3% in the last 9 years from 2013 to 2022.

The breast cancer subtype known as "triple negative" lacks HER2 and/or the hormones progesterone and oestrogen receptors. An unusual subtype of breast cancer is triple negative. triple-negative breast cancer is discovered in 10–20% of cases.

Triple-negative breast cancer is not responsive to hormone treatment or therapies that target the HER2 receptors, such as trastuzumab. Surgery, radiation, and chemotherapy are routinely employed as treatments. Three years later, triple-negative breast cancer has a high chance of getting back and is more likely to spread outside the breast.

The market for triple-negative breast cancer treatment is anticipated to grow as a result of an increase in breast cancer cases, rising demand for treatment options in private hospitals, rising private healthcare provider investments in healthcare infrastructure, rising medical tourism, and improved healthcare standards and practises.

Over the course of the forecast period, companies in the global market for triple-negative breast cancer therapy are likely to benefit from substantial growth possibilities as a result of rising healthcare spending and rising demand for better disease diagnosis. Some are the following development in triple-breast cancer.

• The first PARP inhibitor for the treatment of breast cancer, Lynparza (chemical name: olaparib), received FDA approval in 2018. Women who have HER2-negative metastatic breast cancer and a BRCA1 or BRCA2 mutation who have undergone chemotherapy are treated with Lynparza.

Due to increased research into new treatment pathways and methods to use existing medications more effectively in conjunction or in succession with one another, innovation has given breast cancer patients a great deal of hope for the future. This is further expected to fuel the market for treating triple-negative breast cancer.

Triple-negative breast cancer treatment options are in high demand due to the increased prevalence of breast cancer and blood-related illnesses among the population. Additional factors that are anticipated to contribute to the expansion of the triple-negative breast cancer treatment market size in the near future include an increase in the focus on research and development in therapeutic fields like oncology and the adoption of new treatment therapies for breast cancer.

• Cancer is the top cause of death globally, accounting for 1 in 6 fatalities globally in 2020, according to a World Health Organization (WHO) report released in 2022.
• According to a WHO report released in 2022, 2.26 million incidences of breast cancer exist worldwide.

The market for treating triple-negative breast cancer is therefore anticipated to rise as a result of rising breast cancer prevalence, an ageing population, and changing lifestyles.

How are Manufacturers Aiding towards Market Expansion?

“Growing Attention on Research and Development”

Players in the market are concentrating on the expansion of innovative products to get early market entrance and a large market share for triple-negative breast cancer treatments. Players in the market for treating triple-negative breast cancer are concentrating on enhancing their product offers through partnerships, acquisitions, and marketing.

North America, Europe, and Asian nations like Malaysia, Japan, and China are all observing these major developments. Companies can expedite their market expansion and revenue growth by using such techniques.

For instance,

• Roche and the Kenyan government collaborated to enhance breast cancer treatment in November 2020. This effort was committed to increasing access to services for breast cancer prevention and treatment for women.
• CEL-SCI announced the initiation of development of an immunotherapy for COVID-19 in March 2020. This immunotherapy would treat the condition and lessen tissue damage and other diseases that are associated with it. Several other viral diseases, some cancers, asthmatic asthma and allergies, a few CNS diseases, like Alzheimer's, and autoimmune diseases, such as rheumatoid arthritis, have already been linked to associated antigenic peptide(s) sequences.

The market is expanding due to the increasing need for breast cancer treatments that are effective. The market is anticipated to grow due to a gradual increase in research and development as well as the acceptance of innovative cancer treatment options and industry players are focusing on the expansion of innovative products.

Can the Growth of the Market be affected in Any Way?

“Additional Challenges in Treatment”

The potential for adverse reactions from breast cancer treatments like targeted therapy is also anticipated to restrain the market's expansion for triple-negative breast cancer throughout the targeted period. The market for treatment for triple-negative breast cancer may face additional challenges in the near future due to the challenging reimbursement system and various patent expirations.

The COVID-19 pandemic has had a short-term negative effect on the global market for treating triple-negative breast cancer, affecting both manufacturing industries and oncology healthcare systems. As a result, there has been a delay in diagnosis and the postponement of routine screenings, among other things, in order to cut down on the number of time patients spend in hospitals to reduce the risk of infection.

To combat the COVID-19 epidemic, major financing has been provided by regional governments and top businesses for the expansion of current institutions and the development of new facilities which affect the triple-negative breast cancer market in 2020 and 2021.

Country-wise Insights

Why is the Market for Triple Negative Breast Cancer Treatment Booming in the United States?

“Leading Players' Ongoing Research and Development in the U.S.”

The U.S. accounted for a 39.6% share of the global market in 2022, and a similar trend is expected over the forecast period.

The U.S. dominates the market for triple-negative breast cancer as a result of the rise in cases. In the area, the market for therapies for triple-negative breast cancer will expand throughout the course of the forecast period as a consequence of ongoing research and development activities by top companies.

• According to CDC in 2020, 264,121 new cases of breast cancer were reported in females, and 42,208 women died of breast cancer in the U.S.
• Between 2015 and 2019, over 2 out of 3 of the total cases of breast cancer were determined to be localised, meaning the illness has not spread outside the breast. In 1 in 4 cases of breast cancer, the disease had spread to nearby lymph nodes, tissues, or organs; in contrast, 6% of cases had the disease spread to distant sites.

Why is China Emerging as a Prominent Market for Triple Negative Breast Cancer Treatment?

“Increasing Number of Triple-Negative Breast Cancer Patients”

China held the largest market share of 11.0% of the global market for triple-negative breast cancer treatment in 2022, with a market value of US$ 67.4 Mn.

The top three countries funding breast cancer screening are China, Japan, and Korea in south Asia. Furthermore, China has a strong hold on the Asian market for breast cancer screening. Furthermore, a sizable population of women and domestic NGO operations supports China in its efforts to dominate the Asian market for breast cancer screening.

Because of the influence of traditional Chinese medicine (TCM) in China, the majority of breast cancer patients have undergone any form of TCM treatment. Because TNBC patients are unable to benefit from more advanced endocrine therapy and anti-molecular targeted therapy, Chinese medicine is crucial for TNBC patients hence triple-negative negative cancer market will boosted in upcoming years in china.

Will India be a Lucrative Market for Triple Negative Breast Cancer Treatment?

“Increasing Healthcare Spending”

India held a global market share of 2.4% in 2022 and is projected to progress at a CAGR of 6.1% over the forecast duration.

Due to increased knowledge of the diseases, the triple-negative breast cancer market is anticipated to experience considerable growth. In addition, it is projected that rising disposable income would further fuel the expansion of the triple-negative breast cancer market in India throughout the ensuing years.

The ageing population increased government support for breast cancer screening programmes, and rising breast cancer awareness are the main factors propelling the growth of the breast cancer screening market in Asia.

• A systematic review and meta-analysis on the prevalence of TNBC in the population of India published between 1st January 2010 and 31st March 2020, in the International Journal of Clinical Biostatistics and Biometrics 2022, stated that The prevalence of TNBC in India is 25.04%, which is higher than what is reported in the western literature. Therefore, in-depth research on TNBC patients is required to decide on the best therapy plan for increased survival.

Category-wise Insights

Why is the Demand for Paclitaxel Segment Higher?

“Paclitaxel Dominates in Drug Segment.”

In 2022, on the basis of drugs, the paclitaxel segment accounted for 57.8% market share within the global market. This segment is expected to contribute significant revenue contribution to the global triple-negative breast cancer treatment market, followed by other segments during the forecast period of 2023-2033.

Chemotherapy is the mainstay of treatment for metastatic triple-negative breast cancer (TNBC). Metronomic chemotherapy, which uses continual low-dose chemotherapy delivery, may be an option to increase chemotherapy's effectiveness and prevent systemic toxicity. The idea of metronomic chemotherapy is compatible with the continuous and sustained drug release provided by the paclitaxel-loaded PLGA nanofibers, which are more affordable for patients than chemotherapy.

Which Type of Distribution Channel takes the Highest Share?

“Ease of Availability of Treatment”

The hospital pharmacies sector holds 70.2% of total distribution channels in the global market in 2022 due to increasing awareness among patients related to treatment for TNBC.

In terms of distribution channels, the hospital pharmacies sector is anticipated to be the most lucrative and account for the largest proportion of the global market for treatments for triple-negative breast cancer.

The patient prefers hospital pharmacy as it accessible within the institutional settings, as well as the government provides funding to the patients if required and makes sure that drugs are available at reasonable prices. The hospital pharmacy is the place where every drug is easily available and it is 24 hours in service. Hence, the hospital pharmacy holds more share in the distribution channel segment within the market.

Competitive Landscape

Key players are focusing on acquisitions and licencing deals to increase the company's reach and enhance its product offering. Major companies believe that, in contrast to mergers and acquisitions, partner synergy directly affects growth.

Many manufacturers are funding strong research and development in a number of cancer types, including breast cancer, bladder cancer, cervical cancer, ovarian cancer, and others, in an effort to advance the treatment of triple-negative breast cancer.

Top competitors also concentrate on cutting-edge research in fields like precision medicine and immune-mediated treatment combinations. Through its excellent network, the company places a strong emphasis on providing all customers with high-quality goods.

Players collaborate and licencing one another to find and create novel anti-cancer treatments.

For instance,

• Merck Sharp & Dohme LLC received approval from the FDA i.e. Food and Drug Administration for the combo therapy in 2020 for patients who have advanced triple-negative breast cancer whose tumours have a minimum PD-L1 combined score of 10.
• A clinical partnership between Seattle Genetics and Genentech was established in July 2013 to examine the effectiveness of SGN-LIV1A combined with atezolizumab for the treatment of metastatic triple-negative breast cancer.

Triple Negative Breast Cancer Treatment Market Report Scope

Key Segments of the Triple Negative Breast Cancer Treatment Market

By Drug Type:

• Doxorubicin
• Cyclophosphamide
• Paclitaxel
• Docetaxel
• Carboplatin/Cisplatin
• Others

By Distribution Channel:

• Hospital Pharmacies
• Specialty Cancer Clinics

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

To know more about delivery timeline for this report Contact Sales